

### THE BRITISH ASSOCIATION OF UROLOGICAL SURGEONS

### **SECTION of ONCOLOGY**

BAUS Cancer Registry Analyses of Minimum data set for Urological cancers January 1<sup>st</sup> – 31<sup>st</sup> December 2009

October 2010

#### MEMBERS OF THE EXECUTIVE COMMITTEE

M Aitchison	G Boustead	
R C Kocklebergh	R A Persad	S
V Srinivasin	K S Swami	

J Crew S Prescott D R Greene

#### Copyright

It is important to remind you that, under the Copyright Designs and Patents Act 1988 (CDPA) copyright of this Report, including the charts produced in it, is owned by The British Association of Urological Surgeons Limited (BAUS). Copying or reproducing any part of this material in any other publication without seeking the prior permission of BAUS is a breach of copyright.

Please contact Mrs Sarah Fowler (E-mail: sarah@sarahfowler.org) if you wish to seek the prior consent or licence of BAUS in respect of the above or wish to seek further advice.

### PRODUCED FOR BAUS SECTION OF ONCOLOGY by

Mrs Sarah Fowler BAUS Cancer Registry Manager

#### CONTENTS

Page Number

Introduction	1
Results Summary & Methods of analysis	2
A. Participants and Overall Figures Charts 1 – 17	3
<ul> <li>B. Times between Referral, First Consultation, Diagnosis and Definitive Treatment Charts 18 – 22</li> </ul>	13
C. Histology & Staging Charts 23 – 29	16
D. Initial Treatment Intention & Laparoscopic Surgery Charts 30 - 34	20
E. Clinical Trial Status & Discussion at MDT meeting Charts 35 – 36	23
F. Completeness of Data Charts 37 – 38	24
G. Prostate cancers 1999 – 2009 Charts 39 – 47	25
Appendix – Participating Hospitals 2009	31

#### **INTRODUCTION**

The first data extraction from Nuvola during 2010 has taken place relatively smoothly, despite some expected gremlins which Sarah Fowler has sorted out. We remain hopeful that given time, the web based database will improve capture rates as well as simplify data returns demanded for revalidation. The Executive Committee is also exploring ways of helping and facilitating this process in the future.

Returns from 2009 are marginally down on last year and worryingly the quality and completeness of the submissions has declined still further. One of the core strengths of the BCR data in the past has been the TNM staging information, which set us apart from data held by other national cancer registries. Sadly this data quality is deteriorating (see section C). We believe that the increasing use of in-house systems to bulk-upload the data, as opposed to entering the data on an individual patient basis is the major reason. Please do impress upon those in your departments who do data entry the importance of accuracy and completeness and if possible run some checks on the quality and completeness of your data before it is uploaded if your submission is bulk-uploaded. In addition the reporting function within the web-based database allows you to extract and analyse all the data entered under your name and it is suggested that you do so on a regular basis to ensure its accuracy / completeness.

In line with the theme of this year's Section meeting, we have also included some analyses of the whole dataset on prostate cancer over the last decade.

Finally, the Executive committee would like to see regular publications and updates appearing in the peer reviewed literature, to raise the profile and awareness of the BCR, as well as utilize the valuable information it holds. Anyone is free to apply with a simple application form and instructions available on the website.

Greg Boustead October 2010

#### AUDIT RESULTS SUMMARY January 1<sup>st</sup> – 31<sup>st</sup> December 2009

#### Who took part?

348 consultant urologists from 107 hospital centres in England, Wales, Scotland and Northern Ireland provided data for this study submitting data on 22,756 newly presenting urological tumours from 1st January to 31<sup>st</sup> December 2009. These figures represent approximately 40% of the total UK tumours registered in 2007/2008 (56,611) (the most recent years available). 0.3% (80/22,756) are the private patients of 32 consultants.

#### How were the data analysed?

All information presented here was extracted from the web-based database developed by Nuvola and launched in June 2009. All historical information was uploaded to the system at this time and participants were then encouraged to start entering their data directly, either in the form of bulk uploads or on an individual patient basis. As would be expected there have been a number of teething problems both with the bulk uploading and with individual data entry as users become used to the new system.

Until January 1<sup>st</sup> 2010 data could be returned either by completion of pro formas for each patient or in electronic format using either an Access (Microsoft) database or "in-house" database. The pro formas were entered directly into an Access database, at which time validation comprising mainly of checks for duplicate entries and dates could be carried out. All of this data was transferred to the web-based system and has been included in the analyses.

The data presented here are a summary of that received up to 10<sup>th</sup> September 2010 and relate to diagnoses made during the whole of 2009. The following data was included (this includes the total returns):

- a. Patients for who the date of diagnosis fell within the time period. (01/01/2009 to 31/12/2009). 22,023 registrations (96.8%).
- b. Patients for whom the date of diagnosis was either not included or the patient was a tertiary referral, but the referral date fell within the study period. (01/01/2009 to 31/12/2009) 733 registrations (3.2%).

For the ranked charts (1, 2 & 4) the individual consultant or centre identification numbers were removed and replaced with rank numbers starting at 1. A unique, confidential "Ranking Sheet" was prepared for each surgeon to enable them to identify their rank in every chart. For those charts where overall figures for the entire database are shown the ranking sheet displays the consultant's individual figures. No one else can identify the results of an individual consultant. The ranked comprise single bars, with in addition the 25, 50, and 75 percentiles and are ranked from left to right in the ascending order of the data item being measured. Where percentages are included figures have been rounded up to one decimal point. Unless otherwise stated all analyses represent the 2009 dataset.

A personal ranking sheet for each consultant registering three or more tumours was issued individually to go with this chartbook.

Sarah Fowler BAUS Cancer Registry (BCR) Manager October 2010

#### A. Participants and Overall Figures

The proportion of data returned by bulk upload from in-house systems as oppose to being entered directly onto the web-based database has increased yet again but unfortunately the completeness of data returned by many of these systems remains less so than when individually entered or, prior to January 2010, returned using the specially designed Microsoft Access database, making validation and analyses more complicated.

As in previous years we have incorporated comparison with National Cancer Statistics from 2007/2008 – the latest years available. Comparison with the national data does suggest that our data are representative of the UK as a whole. However when comparing our data with that of the national data we should, as usual, bear in mind the following:

- Our data are only being collected by urologists. We have no way of estimating the number of urological cancers that are not being seen or diagnosed by urologists. In the case of kidney cancer, it seems that a substantial number are never seen by a urological surgeon.
- These data are being presented within ten months of the completion of the year of data collection, 2009, and being compared to national figures from 2007/2008, which are the latest to be published.
- For the majority of participants, there is no specific funding for data collection and the analysis and presentation is entirely funded by the Section of Oncology.

#### BAUS - Register of Newly Presenting Urological Tumours January 1st - December 31st 2009 Who took part

- 348 Consultants from 107 Centres provided data on 22,756 newly presenting urological tumours.
- 0.3% (80/22,756) were from the private patients of 32 Consultants
- Range of Consultants per Centre = 1 11, (Median 4)
- Median number of tumours per Consultant = 29, Range 1 303
- Median number of tumours per Centre = 147, Range 1 1650

#### Total Number of Newly Presenting Tumours Reported per Consultant Median: 29 (Interquartile Range 8 - 70)



#### Chart 2

#### Total Number of Newly Presenting Tumours Reported per Centre Median: 145 (Interquartile Range 35 - 325)



#### Number of Newly presenting Tumours by Organ per Consultant 348 Consultants reported 22,756 Tumours Median Total per Consultant = 29

Organ	Total Number Reported	Median per Consultant	Range
Prostate *			
	13365	14	0 - 219
Bladder			
	5708	6	0 - 84
Kidney			
	2224	2	0 - 42
Testis			
	607	1	0 – 21
Pelvis/Ureter			
	387	0	0 – 13
Penis			
	225	0	0 – 21
Urethra			
	24	0	0 – 1
Prostatic			
Urethra	6	0	0 - 1

\* Includes 22 registrations with High Grade PIN only

#### Chart 4



Total Number of Newly Presenting Tumours Reported per Consultant

N.B. Excludes data returned by centres as a whole

Organ	Number	Percentage of	Median	Age	Males	Females
	Recorded	Total (22756)	Age at Diagnosis	Range		
Prostate *	13365	58.7	70	26-109	13364	
Bladder	5708	25.1	73	22-100	4298	1389
Kidney	2224	9.8	68	18-96	1380	836
Testis	607	2.7	36	15-100	607	
Pelvis/Ureter	387	1.7	74	35-98	252	134
Penis	225	1.0	65	20-98	225	
Urethra	24	0.1	76	45-89	10	14
Prostatic Urethra	6	0.0	72.5	58-87	6	
Other	75	0.3	70	27-98	60	15
Not recorded	135	0.6	69	9-89	110	24

### **Overall Data by Organ**

\* Includes 22 registrations with High Grade PIN only

#### Chart 6

Organ	2009		2004 Number		1999	
Ŭ.	Number	% of Total	Recorded	% of Total	Number	% of Total
	Recorded	(22,756)		(24,532)	Recorded	(19,009)
Prostate						
	13365	58.7	14858#	60.6	9277	48.8
Bladder						
	5708	25.1	6073	24.8	6584	34.6
Kidney						
	2224	9.8	2104	8.6	1661	8.7
Testis						
	607	2.7	750	3.1	838	4.4
Pelvis/Ureter						
	387	1.7	291	1.2	281	1.5
Penis						
	225	1.0	196	0.8	165	0.9
Urethra	24	0.1	29	0.1	-	
Prostatic					-	
Urethra	6	0.0	15	0.1		
Other						
	75	0.3	29	0.1	120	0.6
Not recorded						
	135	0.6	187	0.8	85	0.4

#### Overall Data by Organ by Year

Including registrations with High Grade PIN only: \* 22; # 84

Region	2009		2009	2004	1999
	Total Registrations*	National	BAUS %	BAUS %	BAUS %
	BAUS	figures**	National	National	National
England					
	19231	47314	40.6	50.8	44.0
Scotland					
	962	4188	23	18.8	17.4
Wales					
	2251	3719	60.5	53.3	35.5
Northern Ireland					
	86	1390	6.2	37.6	24.5
Total UK					

56611

39.8

40.7

48 1

#### **Total Registrations per Country** Prostate, Bladder, Kidney, Testis, Pelvis/Ureter & Penile Tumours\*

\*\*England : cancer statistics - registrations of cancer diagnosed in 2007, England. Series MBI no. 38 - 2010 Wales: Welsh Cancer Intelligence & Surveillance Unit – 2008: www.wales.nhs.uk Scotland:Scottish Cancer Registry,Scottish Cancer Intelligence Group, ISD Scotland – 2006: www.isdscotland.org Northern Ireland:Northern Ireland Cancer Registry - 2007 – www.qub.ac.uk/nicr/research-centres

22530

#### Chart 8

#### **Percentage Age Distribution - Prostate Tumours**

BAUS 2009 median: 70 Years; Range 26 -109 (n= 13,056\*) BAUS 2004 median: 72 Years; Range 21 -103 (n= 14,665\*) BAUS 1999 median: 73 Years; Range 21 -100 (n= 8,870\*)



•Age could be calculated when both date of birth and diagnosis date were recorded •The reductions in age at diagnosis over the years are significant at the 95% CI

#### Percentage Age Distribution - Bladder Tumours - Males

BAUS 2009 median: 73 Years; Range 22 -100 (n= 4,221\*) BAUS 2004 median: 73 Years; Range 20 -101 (n= 4,470\*) BAUS 1999 median: 72 Years; Range 6 - 99 (n= 4,664\*)



Percentage in each age group

#### Chart 10



BAUS 1999 median: 75 Years; Range 2 - 98 (n= 1,590\*)



Percentage in each age group

\* Age could be calculated when both date of birth and diagnosis date were recorded

<sup>\*</sup> Age could be calculated when both date of birth and diagnosis date were recorded

#### Percentage Age Distribution - Kidney Tumours - Males

BAUS 2009 median: 67 Years; Range 24- 95 (n=1,334\*) BAUS 2004 median: 66 Years; Range 21 -102 (n= 1,323\*) BAUS 1999 median: 65 Years; Range 24 - 95 (n= 1,000\*)



<sup>\*</sup> Age could be calculated when both date of birth and diagnosis date were recorded

#### Chart 12



BAUS 1999 median: 67 Years; Range 21 - 97 (n= 585\*)



Percentage in each age group

Percentage in each age group

\* Age could be calculated when both date of birth and diagnosis date were recorded



Percentage Age Distribution - Testicular Tumours BAUS 2009 median: 36 Years; Range 15 - 100 (n= 596\*)

\* Age could be calculated when both date of birth and diagnosis date were recorded

#### Chart 14

#### Percentage Age Distribution - Testicular Tumours

Seminoma median age : 38 years; Range 16 - 100; (n = 296\*) Teratoma median age : 29 years; Range 16 - 78; (n = 77\*) Combined seminoma/teratoma median age : 35 years; Range 17 - 65; (n = 26\*)



\* Age could be calculated when both date of birth and diagnosis date were recorded = 596/607 (98%). Histology was reported in 502 of these tumours. (502/596 = 84%), 103 of these were histologies other than the above groups

#### Percentage Age Distribution – Pelvic / UretericTumours – Males BAUS 2009 median: 73 Years; Range 35 - 93 (n= 246\*) BAUS 2004 median: 70 Years; Range 19 - 91 (n= 168\*) BAUS 1999 median: 71 Years; Range 36 - 89 (n= 179\*)

50 45.3 45 <sup>39.9</sup>\_38.6 40 35 31.5 30 26.2 23.7 23.7 25 20 14.3 14.5 15 -13.1 10 8.4 7.9 5 1.2 1.7 12 0.6 0 <40 40-49 50-59 60-69 70-79 >=80 ■2009 ■2004 ■1999

Percentage in each age group

\* Age could be calculated when both date of birth and diagnosis date were recorded

#### Chart 16





Percentage in each age group

\* Age could be calculated when both date of birth and diagnosis date were recorded

#### **Percentage Age Distribution – Penile Tumours**

BAUS 2009 median: 65 Years; Range 20- 98 (n= 220\*) BAUS 2004 median: 66 Years; Range 28 - 93 (n= 182\*) BAUS 1999 median: 66 Years; Range 31 - 95 (n= 158\*)



\* Age could be calculated when both date of birth and diagnosis date were recorded

#### B. Times between referral, consultation, diagnosis and treatment

In this section we have included charts from the 2004 dataset to allow for comparisons.

The overall time from referral to diagnosis has fallen significantly from 2004 and is now the shortest since data collection started in 1999.

Recording of date of definitive treatment has improved this year by 10% with 81% of returns in 2009 including this item however interpretation must still be cautious. In some cases, the date of definitive treatment was recorded as being before the date of diagnosis! Any negative times between diagnosis and definitive treatment date were treated as 0 i.e. definitive treatment date = date of diagnosis.

#### Chart 18





\* Times were calculated when dates of referral, consultation and diagnosis were known and diagnosis date was not before referral date (N = 18,176/22,756 = 80% tumours)

Referral Source was recorded in 17,722/18,176 (98%) cases

# Referral priority was recorded in 94% (10698/11326) GP referrals in England where 2 week rule operates

#### Median Time to First Consultation and Diagnosis in Days by Referral Source in Days Excluding tumours diagnosed before Referral\* - 2004



 \* Times were calculated when dates of referral, consultation and diagnosis were known and diagnosis date was not before referral date (N = 20,189/24,532 = 82% tumours) Referral Source was recorded in 20,020/20,189 (99%) cases
 # Referral priority was recorded in 96% (14601/15152) GP referrals in England where 2 week rule operates

#### Chart 20

Median Time to First Consultation and Diagnosis in Days by Organ Excluding tumours diagnosed before Referral\*



\* Times were calculated when dates of referral, consultation and diagnosis were known and diagnosis date was not before referral date . Date of first consultation not recorded in 1999



#### Median Total Times to Diagnosis in Days - All Referrals Excluding Patients Diagnosed before Referral

#### Chart 22

Organ		Median Time between Referral and Definitive Treatment in days				
	2004	2009	2004	2009		
Prostate	112	62	31	28		
Bladder	63	40	0	0		
Kidney	65	58	0	12		
Testis	16	16	0	0		
Pelvis/Ureter	117	64	6	11		
Penis	41	42	15	1		

Times to Definitive Treatment in Days by Organ – 2009 and 2004 Excluding tumours diagnosed or treated before referral

Definitive treatment date was recorded in 69% tumours (16923/24532) in 2004 and 81% in 2009 (18,442/22,756)

#### C. Histology and Staging

Histological confirmation was only available in 74% of all tumours. This has decreased steadily since 1999 and may be a reflection of the increasing number of returns using in-house data collection systems. Every effort should be made to record data on patients seen in clinics and on the wards, where there is no histological diagnosis.

Participants were asked to return both clinical and, where appropriate, pathological\* TNM categories using the 2002 version of the TNM classification for Urological tumours which were included in the data dictionary sent to all participants.

In order to make interpretation of the resultant information easier each patient was staged, wherever possible, using the classifications as shown in the following charts. If the pathological TNM categories were given and appropriate then these were used for the staging, failing this clinical TNM categories were used.

The number of returns having either the full pathological TNM or clinical TNM categories has decreased significantly since last year and it is assumed that this is again a reflection of the proportion of data being uploaded in bulk from in-house systems. (A substantial proportion of returns do not include any N and M categories or these were recorded as "X" – Cannot be assessed.) A plea for more accurate data recording is given and the suggestion that the BCR data may be more fully recorded if completed during the relevant Multi Disciplinary Team meeting. The data on the following staging charts should therefore be regarded with caution.

\*The pathological assessment of the primary tumour (pT) entails a "resection of the primary tumour or biopsy adequate to evaluate the highest pT category"

#### Chart 23

Organ	2009		2004		1999	
	Ν	%	Ν	%	Ν	%
Prostate						
	10367	77.6	13881	95.3	8605	94.4
Bladder	4568	80.0	5689	96.5	6344	97.8
Kidney	1071	48.2	1425	70.1	1436	88.0
Testis	463	76.3	685	93.6	815	99.4
Pelvis/Ureter	224	57.9	235	83.0	272	97.8
Penis	175	77.8	186	98.9	162	98.8
Urethra	175	79.2	28	98.9 100.0		90.0
Prostatic Urethra	4	66.7	15	100.0	-	
Other or	4	00.7	15	100.0		
Not Recorded	59	28.1	80	30.4	185	94.9
Totals	16950	74.5	22224	92.6	17819	95.3

#### Known Histological Confirmation of Diagnosis by Organ

Staging of Kidney Tumours Staging could be estimated in 40.9% in 2009, 75.4% in 2004 and 92% in 1999



N.B. A pathological staging for Kidney tumours was only included for those where radical or organ conserving surgery was performed

#### Chart 25

Staging of Pelvis / Ureteric Tumours Staging could be estimated in 27.9% in 2009, 72.5% in 2004 and 87.5% in1999



N.B. A pathological staging for Pelvis / Ureteric tumours was only included for those where radical or organ conserving surgery was performed



Staging of Bladder Tumours Staging could be estimated in 58.9% in 2009, 80.5% in 2004 and 94.2% in 1999

#### Chart 27

#### Staging of Prostate Tumours Staging could be estimated in 49.5% in 2009, 67.6% in 2004 and 81.5% in 1999



N.B. A pathological staging for Prostate tumours was only included for those where radical surgery was performed



Staging of Testicular Tumours Staging could be estimated in 50.9% in 2009, 69.2% in 2004 and 86.2% in1999

#### Chart 29

Staging of Penile Tumours Staging could be estimated in 41.8% in 2009, 65.8% in 2004 and 90.1% in1999



#### **D.** Treatment Intention & Laparoscopic procedures

#### Chart 30

Organ	Curative		Palliative		No active anti-cancer treatment		% of Total Tumours
(Number Known)	Ν	%	N	%	N	%	Reported
Prostate (7046)							
	3527	50.1	2227	31.6	1292	18.3	52.7
Bladder (3868)	3429	88.7	264	6.8	175	4.5	67.8
Kidney (1244)	850	68.3	222	17.8	172	13.8	55.9
Testis (296)	292	98.6	4	1.4		0.0	48.8
Pelvis/Ureter (184)	140	76.1	27	14.7	17	9.2	47.5
Penis (104)	94	90.4	5	4.8	5	4.8	46.2
Urethra (14)	12	85.7	1	7.1	1	7.1	58.3
Prostatic Urethra (2)	2	100.0			_		33.3

#### **Initial Treatment Intention by Organ Percentage & Total of Known Intent - 2009**

#### Chart 31

#### Initial Treatment Intention by Organ Percentage & Total of Known Intent - 2004

Organ	Curative		Palliative		No active anti-cancer treatment		% of Total Tumours
(Number Known)	Ν	%	Ν	%	N	%	Reported
Prostate (11615)	5131	44.2	4750	40.9	1734	14.9	78.2
Bladder (5132)	4574	89.1	450	8.8	108	2.1	84.5
Kidney (1765)	1273	72.1	332	18.8	160	9.1	83.9
Testis (620)	613	98.9	6	1.0	1	0.2	82.7
Pelvis/Ureter (234)	189	80.8	32	13.7	13	5.6	80.4
Penis (146)	132	90.4	9	6.2	5	3.4	74.5
Urethra (25)	15	60.0	7	28.0	3	12.0	86.2
Prostatic Urethra (11)	7	63.6	2	18.2	2	18.2	73.3

Organ	Curative		Palliative		Surveillance		% of Total Tumours
(Number Known)	N	%	Ν	%	Ν	%	Reported
Prostate (8291)							
	2465	29.7	4483	54.1	1343	16.2	69.1
Bladder (6105)							
	5096	83.5	820	13.4	189	3.1	73.4
Kidney (1579)							
• • •	1191	75.4	307	19.5	81	5.1	70.6
Testis (789)							
. ,	764	96.8	8	1.0	17	2.2	70.9
Pelvis/Ureter (268)							
	230	85.8	30	11.2	8	3.0	75.8
Penis (153)							
	136	88.9	15	<b>9.</b> 8	2	1.3	64.7

#### **Initial Treatment Intention by Organ Percentage & Total of Known Intent - 1999**

#### Chart 33

#### Laparoscopic Procedures Performed as Percentage of Total Procedures reported\*

Organ	2009			2004		2001			
	Open	Lap	Lap as % total	Open	Lap	Lap as % total	Open	Lap	Lap as % total
Prostate	1371	323	23.6	2709	290	9.7	3838	45	1.2
Kidney	753	288	38.2	1345	169	11.2	1632	31	1.9
Pelvis / Ureter	140	37	26.4	187	34	15.4	295	6	2.0
Bladder	4080	11	0.3	5232	4	0.1	6854	7	0.1

\* Laparoscopic procedures not recorded until 2001

Staging	Prostate			Bladder			Kidney			Pelvis/Ureter		
	2009	2004	2001	2009	2004	2001	2009	2004	2001	2009	2004	2001
Stage 0a	N/A	N/A	N/A	2	1	1	N/A	N/A	N/A	3	9	2
Stage I		-	-	-	2	-	74	107	22	2	6	3
Stage II	92	247	40	1	1	3	10	14	3	3	5	
Stage III	5	21	3	-	-	2	11	12	1	1	2	1
Stage IV	2	-	2	-	-	-	6	4	-	-	-	
Not Recorded	224	22	-	8	-	1	187	32	6	28	12	-
Totals	323	290	45	11	4	7	288	169	32	37	34	6

#### Laparoscopic Surgery by Organ and Stage Total Numbers recorded

### E. Clinical Trial Status and discussion at MDT meeting Chart 35

Trial Status	2009	2004		2002*		
	Ν	%	Ν	%	N	%
Patient eligible, consented to and entered trial	284	1.2	554	2.3	597	2.1
Patient eligible for trial but declined entry	121	0.5	148	0.6	144	0.5
Patient ineligible for trial	677	3.0	1231	5.0	1088	3.8
Patient not considered for trial	2844	12.5	7839	32.0	8746	30.8
Clinical trial status unknown	5737	25.2	4452	18.1	4879	17.2
Not Recorded	13093	57.5	10308	42.0	12897	45.5

### **Clinical Trial Status**

\* First year recorded

#### Chart 36

## Was the Patient discussed at an MDT meeting with formation of a management plan?

Response	2009			2003*		
	Ν	%	Ν	%		
Yes	18804	82.6	14967	55.0		
No	1658	7.3	9414	34.6		
Not Known or Not Recorded	2294	10.1	2844	10.4		

\* First year recorded

#### F. Completeness of Data

#### Chart 37

#### Completeness of Data -1 Percentage and numbers of Total Returns unknown

Data Item	2009		2004		1999	
	Number	% of	Number	% of	Number	% of
	Unknown	Total	Unknown	Total	Unknown	Total
		Returns		Returns		Returns
		22756		24532		22309
Centre no or Cons no	0	0	0	0	9	0.04
Hospital number	#3193	14.0	**760	3.1	***257	1.4
NHS number	#	-	2975	12.1	6946	36.5
Postcode	##	-	948	3.9	1319	6.9
Sex	32	0.1	113	0.5	118	0.6
Date of Birth	###543	2.4	244	1.0	217	1.1
Organ	126	0.5	181	0.7	83	0.4
Date of Diagnosis	199	0.9	84	0.3	604	3.2
Referral Source	1284	5.6	1592	6.5	1096	5.8
Priority of GP Referrals	1019/14251	7.1	776/17123	4.5	-	-
Date of Referral	1513	6.6	2419	9.9	1820	9.6
Date of First Consultation	2156	9.5	2101	8.6	-	-
Date of Definitive Treatment	4271	18.8	7707	31.4	-	-
Delay to Diagnosis	2330	10.2	2738	11.2	-	-
Histological confirmation	104	0.5	593	2.4	321	1.7
Basis of diagnosis if no	2271/5706	39.8	175/1713	10.2	71/875	8.1
Histology						

# - NHS number main patient identifier -random one automatically created if missing; ## No longer extracted; ### Age at diagnosis;

\*\* includes 160 pp + 220 from 1 centre with data extraction problems ; \*\*\* includes 198 pp

#### Chart 38

#### **Completeness of Data -2 Percentage and numbers of Total Returns unknown**

Data Item	2009		2004		1999	
	Number	% of Total	Number	% of Total	Number	% of Total
	Unknown	Returns	Unknown	Returns	Unknown	Returns
		23174		24532		19009
Histology	583/16946	3.4	787/22226	3.5	258/17813	1.4
Differentiation	7090/16946	41.8	5230/22226	23.5	2220/17813	12.4
Clinical T Category	13652	60.0	2669	10.9	3357	17.7
Clinical N Category	15610	68.6	4057	16.5	6555	34.5
Clinical M Category	15263	67.1	4453	18.2	6467	34.0
Pathological T Category	11098/16946	65.5	9158/22226	41.2	6223/17813	34.9
Pathological N Category	12883/16946	76.0	9920/22226	44.6	9061/17813	50.9
Pathological M Category	12396/16946	73.1	9930/22226	44.7	9055/17813	50.8
PSA at time of Diagnosis	306/13365	2.3	2276/14858	15.3	1071/9277	11.5
Gleason Scores	3145/13365	23.5	2102/14858	14.1	-	-
Testicular S Category	534/607	88.0	436/750	58.1	307/838	36.6
Treatment Intention	9960	43.8	4949	20.2	1646	8.7
Treatment Type	322/11134	2.9	703/17559	4.0	331/15714	2.1
Clinical Trial Status	13093	57.5	10705	43.6	-	-
Discussed at MDT	2294	10.1	1907	7.8	-	-
Pathological Ref. No.	8152	35.8	6322	25.8	-	-

#### G. Prostate Cancers – 1999 to 2009

The BAUS Cancer Registry (BCR) currently has data on over 300,000 new urological cancers diagnosed since 1998. We have undertaken an ad hoc analysis of all the prostate cancer entries (154,326) showing trends over the years 2000, 2003, 2006 and 2009. This is estimated to represent between 40 and 50% of all new prostate cancer registrations during this time period.

#### Chart 39



### BCR Prostate cancer registrations by date of diagnosis



#### Chart 41



### Age at presentation



Trends in Gleason score at

#### Chart 43

### **Trends in PSA at presentation -1**





Trends in PSA at presentation - 2

#### Chart 45

### **Time to First Consultation**



# Time from first consultation to diagnosis



#### Chart 47

### **Time from Referral to Diagnosis**





### **Treatment intention**

#### **Participating Hospital Centres 2009**

We are grateful to Consultants from the following Centres / Trusts who provided data for the analyses of the 2009 newly diagnosed registry data:

Aberdeen Royal Infirmary Airedale General Hospital Alexandra Hospital; Kidderminster General Hospital; Worcester Royal Infirmary Altnagelvin Area Hospital Arrowe Park Hospital Barnet & Chase Farm Hospital **Barnsley Hospital NHS Foundation Trust Bedford Hospital Bradford Royal Infirmary Castle Hill Hospital Chesterfield & North Derbyshire Churchill Hospital City Hospitals Sunderland NHS Foundation** Trust **Colchester Hospital University NHS Foundation Trust** Cwm-Taf LHB (Royal Glamorgan/Prince Charles) **Derby Hospitals NHS Foundation Trust Derriford Hospital** Diana, Princess of Wales Hospital; Goole & District Hospital; Scunthorpe General Hospital **Doncaster & Bassetlaw Hospitals NHS Trust Dorset County Hospital** East Lancashire Hospitals NHS Trust East Sussex Hospitals NHS Trust **Epsom and St Helier University Hospitals Freeman Hospital** Frimley Park Hospital Gartnavel General Hospital George Eliot Hospital Glan Clwyd Hospital **Glasgow Royal Infirmary** Gloucestershire Royal Hospital Great Western Hospital, Swindon Guy's & Thomas's Hospital Hemel Hempstead General Hospital; Mount Vernon & Watford Hospitals Hereford Hospitals NHS Trust Hillingdon Hospital Huddersfield Royal Infirmary **Kettering General Hospital** 

Leicester General Hospital Leighton Hospital Lincoln & Louth NHS Trust Lister Hospital; Queen Elizabeth II Hospital, Welwyn Manchester Royal Infirmary Medway Maritime Hospital Milton Keynes General Hospital Nevill Hall Hospital New Cross Hospital Noble's Isle of Man Hospital Norfolk & Norwich Hospital North Bristol NHS Trust North Devon District Hospital North Hampshire Hospital North Middlesex Hospital Northampton General Hospital Nottingham City Hospital Pinderfields Hospital Portsmouth Hospitals NHS Trust Prince Philip Hospital Princess Alexandra Hospital, Harlow Private Patients General Centre Queen Elizabeth Hospital, Birmingham Queen Elizabeth Hospital, King's Lynn Queen's Hospital Burton Royal Alexandra Hospital (Paisley) **Royal Berkshire NHS Foundation Trust Royal Bolton Hospital NHS Foundation Trust** Royal Bournemouth Hospital **Royal Cornwall Hospital Royal Gwent Hospital Royal Hallamshire Hospital** Royal Liverpool University Hospital Royal Preston Hospital Royal Surrey County Hospital **Royal Sussex County Hospital** Royal West Sussex NHS Trust Salford Royal NHS Foundation Trust Salisbury District Hospital Sandwell District General Hospital Scarborough Hospital Southampton General Hospital

- Southend University Hospital NHS Foundation Trust Southern General Hospital Southport & Ormskirk NHS Trust St Bartholomew's Hospital St George's Hospital St James's University Hospital St Mary's Hospital, IOW **Stobhill Hospital** Stracathro Hospital; Perth Royal Infirmary; Ninewells Hospital Taunton and Somerset Hospital The Countess of Chester Hospital The Royal Oldham Hospital **Torbay Hospital Trafford General Hospital** United Bristol Health Care Trust
- University Hospital of North Durham University Hospital of North Stafford University Hospital of Wales Walsgrave Hospital Warwick Hospital West Wales General Hospital Wexham Park Hospital Whipps Cross Hospital Whiston Hospital Withington Hospital Worthing Hospital Wrexham Maelor Hospital Wrightington, Wigan and Leigh NHS Foundation Trust York District Hospital Ysbyty Gwynedd Hospital